Display options
Cite
Coughlin JM, Yang K, Marsman A, et al. A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia. Mol Psychiatry. 2020;26(7):3502-3511doi: 10.1038/s41380-020-00901-5.
Coughlin, J. M., Yang, K., Marsman, A., Pradhan, S., Wang, M., Ward, R. E., Bonekamp, S., Ambinder, E. B., Higgs, C. P., Kim, P. K., Edwards, J. A., Varvaris, M., Wang, H., Posporelis, S., Ma, S., Tsujimura, T., Edden, R. A. E., Pomper, M. G., Sedlak, T. W., Fournier, M., Schretlen, D. J., Cascella, N. G., Barker, P. B., & Sawa, A. (2021). A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia. Molecular psychiatry, 26(7), 3502-3511. https://doi.org/10.1038/s41380-020-00901-5
Coughlin, Jennifer M, et al. "A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia." Molecular psychiatry vol. 26,7 (2021): 3502-3511. doi: https://doi.org/10.1038/s41380-020-00901-5
Coughlin JM, Yang K, Marsman A, Pradhan S, Wang M, Ward RE, Bonekamp S, Ambinder EB, Higgs CP, Kim PK, Edwards JA, Varvaris M, Wang H, Posporelis S, Ma S, Tsujimura T, Edden RAE, Pomper MG, Sedlak TW, Fournier M, Schretlen DJ, Cascella NG, Barker PB, Sawa A. A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia. Mol Psychiatry. 2021 Jul;26(7):3502-3511. doi: 10.1038/s41380-020-00901-5. Epub 2020 Oct 19. PMID: 33077854.
Copy Download .nbib Format: NLM
Share it on

Mol Psychiatry. 2021 Jul;26(7):3502-3511. doi: 10.1038/s41380-020-00901-5. Epub 2020 Oct 19.

A multimodal approach to studying the relationship between peripheral glutathione, brain glutamate, and cognition in health and in schizophrenia.

Molecular psychiatry

Jennifer M Coughlin, Kun Yang, Anouk Marsman, Subechhya Pradhan, Min Wang, Rebecca E Ward, Susanne Bonekamp, Emily B Ambinder, Cecilia P Higgs, Pearl K Kim, Jamie A Edwards, Mark Varvaris, Hongxing Wang, Sotirios Posporelis, Shuangchao Ma, Tsuyoshi Tsujimura, Richard A E Edden, Martin G Pomper, Thomas W Sedlak, Margot Fournier, David J Schretlen, Nicola G Cascella, Peter B Barker, Akira Sawa

Affiliations

  1. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  2. Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  3. F. M. Kirby Center for Functional Brain Imaging, Kennedy Krieger Institute, Baltimore, MD, USA.
  4. Department of Health Sciences Informatics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.
  5. Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland.
  6. Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [email protected].
  7. Department of Neuroscience, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [email protected].
  8. Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [email protected].
  9. Department of Genetic Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [email protected].
  10. Department of Mental Health, Johns Hopkins University School of Medicine, Baltimore, MD, USA. [email protected].

PMID: 33077854 DOI: 10.1038/s41380-020-00901-5

Abstract

Involvement of oxidative stress in the pathophysiology of schizophrenia (SZ) is suggested by studies of peripheral tissue. Nonetheless, it is unclear how such biological changes are linked to relevant, pathological neurochemistry, and brain function. We designed a multi-faceted study by combining biochemistry, neuroimaging, and neuropsychology to test how peripheral changes in a key marker for oxidative stress, glutathione (GSH), may associate with central neurochemicals or neuropsychological performance in health and in SZ. GSH in dorsal anterior cingulate cortex (dACC) was acquired as a secondary 3T

© 2020. The Author(s), under exclusive licence to Springer Nature Limited.

References

  1. Landek-Salgado MA, Faust TE, Sawa A. Molecular substrates of schizophrenia: homeostatic signaling to connectivity. Mol Psychiatry. 2016;21:10–28. - PubMed
  2. Emiliani FE, Sedlak TW, Sawa A. Oxidative stress and schizophrenia: recent breakthroughs from an old story. Curr Opin Psychiatry. 2014;27:185–90. - PubMed
  3. Kulak A, Steullet P, Cabungcal JH, Werge T, Ingason A, Cuenod M, et al. Redox dysregulation in the pathophysiology of schizophrenia and bipolar disorder: insights from animal models. Antioxid Redox Signal. 2013;18:1428–43. - PubMed
  4. Owen MJ, Sawa A, Mortensen PB. Schizophrenia. Lancet. 2016;388:86–97. - PubMed
  5. Koga M, Serritella AV, Sawa A, Sedlak TW. Implications for reactive oxygen species in schizophrenia pathogenesis. Schizophr Res. 2016;176:52–71. - PubMed
  6. Zhang Y, Catts VS, Shannon Weickert C. Lower antioxidant capacity in the prefrontal cortex of individuals with schizophrenia. Aust N. Z J Psychiatry. 2018;52:690–8. - PubMed
  7. Flatow J, Buckley P, Miller BJ. Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry. 2013;74:400–9. - PubMed
  8. Fraguas D, Díaz-Caneja CM, Ayora M, Hernández-Álvarez F, Rodríguez-Quiroga A, Recio S, et al. Oxidative stress and inflammation in first-episode psychosis: a systematic review and meta-analysis. Schizophr Bull. 2019;45:742–51. - PubMed
  9. Nguyen TT, Eyler LT, Jeste DV. Systemic biomarkers of accelerated aging in schizophrenia: a critical review and future directions. Schizophr Bull. 2018;44:398–408. - PubMed
  10. Dietrich-Muszalska A, Olas B, Głowacki R, Bald E. Oxidative/nitrative modifications of plasma proteins and thiols from patients with schizophrenia. Neuropsychobiology. 2009;59:1–7. - PubMed
  11. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1178–83. - PubMed
  12. Raffa M, Barhoumi S, Atig F, Fendri C, Kerkeni A, Mechri A. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:371–5. - PubMed
  13. Ruiz-Litago F, Seco J, Echevarría E, Martínez-Cengotitabengoa M, Gil J, Irazusta J, et al. Adaptive response in the antioxidant defence system in the course and outcome in first-episode schizophrenia patients: a 12-months follow-up study. Psychiatry Res. 2012;200:218–22. - PubMed
  14. Nucifora LG, Tanaka T, Hayes LN, Kim M, Lee BJ, Matsuda T, et al. Reduction of plasma glutathione in psychosis associated with schizophrenia and bipolar disorder in translational psychiatry. Transl Psychiatry. 2017;7:e1215. - PubMed
  15. Vidović B, Milovanović S, Dorđević B, Kotur-Stevuljević J, Stefanović A, Ivanišević J, et al. Effect of alpha-lipoic acid supplementation on oxidative stress markers and antioxidative defense in patients with schizophrenia. Psychiatr Danub. 2014;26:205–13. - PubMed
  16. Vidović B, Stefanović A, Milovanović S, Ðorđević B, Kotur-Stevuljević J, Ivanišević J, et al. Associations of oxidative stress status parameters with traditional cardiovascular disease risk factors in patients with schizophrenia. Scand J Clin Lab Invest. 2014;74:184–91. - PubMed
  17. Fukushima T, Iizuka H, Yokota A, Suzuki T, Ohno C, Kono Y, et al. Quantitative analyses of schizophrenia-associated metabolites in serum: serum D-lactate levels are negatively correlated with gamma-glutamylcysteine in medicated schizophrenia patients. PLoS One. 2014;9:e101652. - PubMed
  18. Tsai MC, Liou CW, Lin TK, Lin IM, Huang TL. Changes in oxidative stress markers in patients with schizophrenia: the effect of antipsychotic drugs. Psychiatry Res. 2013;209:284–90. - PubMed
  19. Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naive first-episode schizophrenic patients. BMC Psychiatry. 2011;11:124. - PubMed
  20. Altuntas I, Aksoy H, Coskun I, Cayköylü A, Akçay F. Erythrocyte superoxide dismutase and glutathione peroxidase activities, and malondialdehyde and reduced glutathione levels in schizophrenic patients. Clin Chem Lab Med. 2000;38:1277–81. - PubMed
  21. Do KQ, Trabesinger AH, Kirsten-Krüger M, Lauer CJ, Dydak U, Hell D, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721–8. - PubMed
  22. Matsuzawa D, Hashimoto K. Magnetic resonance spectroscopy study of the antioxidant defense system in schizophrenia. Antioxid Redox Signal. 2011;15:2057–65. - PubMed
  23. Matsuzawa D, Obata T, Shirayama Y, Nonaka H, Kanazawa Y, Yoshitome E, et al. Negative correlation between brain glutathione level and negative symptoms in schizophrenia: a 3T 1H-MRS study. PLoS One. 2008;3:e1944. - PubMed
  24. Monin A, Baumann PS, Griffa A, Xin L, Mekle R, Fournier M, et al. Glutathione deficit impairs myelin maturation: relevance for white matter integrity in schizophrenia patients. Mol Psychiatry. 2015;20:827–38. - PubMed
  25. Terpstra M, Vaughan TJ, Ugurbil K, Lim KO, Schulz SC, Gruetter R. Validation of glutathione quantitation from STEAM spectra against edited 1H NMR spectroscopy at 4T: application to schizophrenia. MAGMA. 2005;18:276–82. - PubMed
  26. Wood SJ, Berger GE, Wellard RM, Proffitt TM, McConchie M, Berk M, et al. Medial temporal lobe glutathione concentration in first episode psychosis: a 1H-MRS investigation. Neurobiol Dis. 2009;33:354–7. - PubMed
  27. Dwyer GE, Hugdahl K, Specht K, Grüner R. Current Practice and New Developments in the Use of In Vivo Magnetic Resonance Spectroscopy for the Assessment of Key Metabolites Implicated in the Pathophysiology of Schizophrenia. Curr Top Med Chem. 2018;18:1908–24. - PubMed
  28. Kumar J, Liddle EB, Fernandes CC, Palaniyappan L, Hall EL, Robson SE, et al. Glutathione and glutamate in schizophrenia: a 7T MRS study. Mol Psychiatry. 2020;25:873–82. - PubMed
  29. Lesh TA, Maddock RJ, Howell A, Wang H, Tanase C, Daniel Ragland J, et al. Extracellular free water and glutathione in first-episode psychosis-a multimodal investigation of an inflammatory model for psychosis. Mol Psychiatry. 2019. https://doi.org/10.1038/s41380-019-0428-y . Online ahead of print. - PubMed
  30. Girgis RR, Baker S, Mao X, Gil R, Javitt DC, Kantrowitz JT, et al. Effects of acute N-acetylcysteine challenge on cortical glutathione and glutamate in schizophrenia: A pilot in vivo proton magnetic resonance spectroscopy study. Psychiatry Res. 2019;275:78–85. - PubMed
  31. Hafizi S, Da Silva T, Meyer JH, Kiang M, Houle S, Remington G, et al. Interaction between TSPO-a neuroimmune marker-and redox status in clinical high risk for psychosis: a PET-MRS study. Neuropsychopharmacology. 2018;43:1700–5. - PubMed
  32. Das TK, Javadzadeh A, Dey A, Sabesan P, Théberge J, Radua J, et al. Antioxidant defense in schizophrenia and bipolar disorder: A meta-analysis of MRS studies of anterior cingulate glutathione. Prog Neuropsychopharmacol Biol Psychiatry. 2019;91:94–102. - PubMed
  33. Xin L, Mekle R, Fournier M, Baumann PS, Ferrari C, Alameda L, et al. Genetic polymorphism associated prefrontal glutathione and its coupling with brain glutamate and peripheral redox status in early psychosis. Schizophr Bull. 2016;42:1185–96. - PubMed
  34. Sedlak TW, Nucifora LG, Koga M, Shaffer LS, Higgs C, Tanaka T, et al. Sulforaphane augments glutathione and influences brain metabolites in human subjects: a clinical pilot study. Mol Neuropsychiatry. 2018;3:214–22. - PubMed
  35. Cabungcal JH, Counotte DS, Lewis E, Tejeda HA, Piantadosi P, Pollock C, et al. Juvenile antioxidant treatment prevents adult deficits in a developmental model of schizophrenia. Neuron. 2014;83:1073–84. - PubMed
  36. Johnson AW, Jaaro-Peled H, Shahani N, Sedlak TW, Zoubovsky S, Burruss D, et al. Cognitive and motivational deficits together with prefrontal oxidative stress in a mouse model for neuropsychiatric illness. Proc Natl Acad Sci USA. 2013;110:12462–7. - PubMed
  37. Baumann PS, Griffa A, Fournier M, Golay P, Ferrari C, Alameda L, et al. Impaired fornix-hippocampus integrity is linked to peripheral glutathione peroxidase in early psychosis. Transl Psychiatry. 2016;6:e859. - PubMed
  38. Geiser E, Retsa C, Knebel JF, Ferrari C, Jenni R, Fournier M, et al. The coupling of low-level auditory dysfunction and oxidative stress in psychosis patients. Schizophr Res. 2017;190:52–59. - PubMed
  39. Lavoie S, Berger M, Schlögelhofer M, Schäfer MR, Rice S, Kim SW, et al. Erythrocyte glutathione levels as long-term predictor of transition to psychosis. Transl Psychiatry. 2017;7:e1064. - PubMed
  40. Shirai Y, Fujita Y, Hashimoto R, Ohi K, Yamamori H, Yasuda Y, et al. Dietary intake of sulforaphane-rich broccoli sprout extracts during juvenile and adolescence can prevent phencyclidine-induced cognitive deficits at adulthood. PLoS One. 2015;10:e0127244. - PubMed
  41. Koga M, Serritella AV, Messmer MM, Hayashi-Takagi A, Hester LD, Snyder SH, et al. Glutathione is a physiologic reservoir of neuronal glutamate. Biochem Biophys Res Commun. 2011;409:596–602. - PubMed
  42. Steullet P, Cabungcal JH, Monin A, Dwir D, O’Donnell P, Cuenod M, et al. Redox dysregulation, neuroinflammation, and NMDA receptor hypofunction: A “central hub” in schizophrenia pathophysiology? Schizophr Res. 2016;176:41–51. - PubMed
  43. Sedlak TW, Paul BD, Parker GM, Hester LD, Snowman AM, Taniguchi Y, et al. The glutathione cycle shapes synaptic glutamate activity. Proc Natl Acad Sci USA. 2019;116:2701–6. - PubMed
  44. Gasquoine PG. Localization of function in anterior cingulate cortex: from psychosurgery to functional neuroimaging. Neurosci Biobehav Rev. 2013;37:340–8. - PubMed
  45. Marsman A, van den Heuvel MP, Klomp DW, Kahn RS, Luijten PR, Hulshoff Pol HE. Glutamate in schizophrenia: a focused review and meta-analysis of ¹H-MRS studies. Schizophr Bull. 2013;39:120–9. - PubMed
  46. Poels EM, Kegeles LS, Kantrowitz JT, Slifstein M, Javitt DC, Lieberman JA, et al. Imaging glutamate in schizophrenia: review of findings and implications for drug discovery. Mol Psychiatry. 2014;19:20–29. - PubMed
  47. Wijtenburg SA, Wright SN, Korenic SA, Gaston FE, Ndubuizu N, Chiappelli J, et al. Altered glutamate and regional cerebral blood flow levels in schizophrenia: A (1)H-MRS and pCASL study. Neuropsychopharmacology. 2017;42:562–71. - PubMed
  48. Egerton A, Broberg BV, Van Haren N, Merritt K, Barker GJ, Lythgoe DJ, et al. Response to initial antipsychotic treatment in first episode psychosis is related to anterior cingulate glutamate levels: a multicentre (1)H-MRS study (OPTiMiSE). Mol Psychiatry. 2018;23:2145–55. - PubMed
  49. Ojeda N, Peña J, Schretlen DJ, Sánchez P, Aretouli E, Elizagárate E, et al. Hierarchical structure of the cognitive processes in schizophrenia: the fundamental role of processing speed. Schizophr Res. 2012;135:72–78. - PubMed
  50. Schretlen DJ, Vannorsdall T. Calibrated ideational fluency assessment professional manual. Lutz, FL: Psychological Assessment Resources; 2010. - PubMed
  51. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total and oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem. 1969;27:502–22. - PubMed
  52. Provencher SW. Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med. 1993;30:672–9. - PubMed
  53. Ongür D, Prescot AP, Jensen JE, Cohen BM, Renshaw PF. Creatine abnormalities in schizophrenia and bipolar disorder. Psychiatry Res. 2009;172:44–48. - PubMed
  54. Tibbo PG, Bernier D, Hanstock CC, Seres P, Lakusta B, Purdon SE. 3-T proton magnetic spectroscopy in unmedicated first episode psychosis: a focus on creatine. Magn Reson Med. 2013;69:613–20. - PubMed
  55. Barch DM, Bustillo J, Gaebel W, Gur R, Heckers S, Malaspina D, et al. Logic and justification for dimensional assessment of symptoms and related clinical phenomena in psychosis: relevance to DSM-5. Schizophr Res. 2013;150:15–20. - PubMed
  56. McClure MM, Bowie CR, Patterson TL, Heaton RK, Weaver C, Anderson H, et al. Correlations of functional capacity and neuropsychological performance in older patients with schizophrenia: evidence for specificity of relationships? Schizophr Res. 2007;89:330–8. - PubMed
  57. Sánchez P, Ojeda N, Peña J, Elizagárate E, Yoller AB, Gutiérrez M, et al. Predictors of longitudinal changes in schizophrenia: the role of processing speed. J Clin Psychiatry. 2009;70:888–96. - PubMed
  58. Schaefer J, Giangrande E, Weinberger DR, Dickinson D. The global cognitive impairment in schizophrenia: consistent over decades and around the world. Schizophr Res. 2013;150:42–50. - PubMed
  59. Houghton CA. Sulforaphane: its “coming of age” as a clinically relevant nutraceutical in the prevention and treatment of chronic disease. Oxid Med Cell Longev. 2019;2019:2716870. - PubMed
  60. Shiina A, Kanahara N, Sasaki T, Oda Y, Hashimoto T, Hasegawa T, et al. An open study of sulforaphane-rich broccoli sprout extract in patients with schizophrenia. Clin Psychopharmacol Neurosci. 2015;13:62–67. - PubMed
  61. Singh K, Connors SL, Macklin EA, Smith KD, Fahey JW, Talalay P, et al. Sulforaphane treatment of autism spectrum disorder (ASD). Proc Natl Acad Sci USA. 2014;111:15550–5. - PubMed
  62. Reid MA, White DM, Kraguljac NV, Lahti AC. A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia. Schizophr Res. 2016;170:341–50. - PubMed
  63. Kaminski J, Gleich T, Fukuda Y, Katthagen T, Gallinat J, Heinz A, et al. Association of cortical glutamate and working memory activation in patients with schizophrenia: a multimodal proton magnetic resonance spectroscopy and functional magnetic resonance imaging study. Biol Psychiatry. 2020;87:225–33. - PubMed

Publication Types

Grant support